Cargando…

Periostin and mesothelin: Potential predictors of malignant progression in intrahepatic cholangiocarcinoma

Detalles Bibliográficos
Autores principales:	Mandrekar, Pranoti, Cardinale, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944583/ https://www.ncbi.nlm.nih.gov/pubmed/29761164 http://dx.doi.org/10.1002/hep4.1189

Ejemplares similares

Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model
por: Manzanares, Miguel Á., et al.
Publicado: (2017)

Periostin promotes malignant potential by induction of epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma
por: Mino, Masaaki, et al.
Publicado: (2017)

Clustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosis
por: Thuwajit, Chanitra, et al.
Publicado: (2017)

Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
por: Yu, Liping, et al.
Publicado: (2010)

Targeting Epigenetic Mechanisms to Alleviate Alcoholic Steatosis
por: Mandrekar, Pranoti
Publicado: (2020)

PRDX6 knockout restrains the malignant progression of intrahepatic cholangiocarcinoma
por: Li, Hong, et al.
Publicado: (2022)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Intrinsic and environmental factors in intrahepatic cholangiocarcinoma development
por: Yuan, Detian, et al.
Publicado: (2017)

Pushing the limits for the surgical treatment of intrahepatic cholangiocarcinoma
por: Choi, Woo Jin, et al.
Publicado: (2023)

Surgical Management of Intrahepatic Cholangiocarcinoma: Quo Vadis
por: Moris, Dimitrios
Publicado: (2023)

MEK Inhibition: A New Ally in Immunotherapy for Intrahepatic Cholangiocarcinoma
por: Loeuillard, Emilien, et al.
Publicado: (2021)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression
por: Mancarella, Serena, et al.
Publicado: (2022)

Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma
por: Jeong, Seogsong, et al.
Publicado: (2016)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Predictors of Distant Metastasis and Prognosis in Newly Diagnosed T1 Intrahepatic Cholangiocarcinoma
por: Guo, Kaibo, et al.
Publicado: (2023)

Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
por: Lamarca, Angela, et al.
Publicado: (2021)

From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Advancing hepatology research: Excellence in open access
por: Mandrekar, Pranoti
Publicado: (2017)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Two Varieties of Intrahepatic Cholangiocarcinoma
por: Nagorney, David M.
Publicado: (1994)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
por: Inoue, Yoshiyuki, et al.
Publicado: (2012)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Intrahepatic cholangiocarcinoma: current perspectives
por: Buettner, Stefan, et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Molecular heterogeneity in intrahepatic cholangiocarcinoma
por: Ahn, Keun Soo, et al.
Publicado: (2020)

Recurrent Intrahepatic Cholangiocarcinoma – Review
por: Bekki, Yuki, et al.
Publicado: (2021)

Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
por: Borakati, Aditya, et al.
Publicado: (2022)

Surgical Aspects of Intrahepatic Cholangiocarcinoma
por: Kupietzky, Amram, et al.
Publicado: (2022)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma
por: Owen, Mackenzie, et al.
Publicado: (2023)

Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure
por: Carpino, Guido, et al.
Publicado: (2019)

Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma
por: Granata, Vincenza, et al.
Publicado: (2022)

The Japanese Clinical Practice Guidelines for intrahepatic cholangiocarcinoma: a comparison with Western guidelines
por: Buettner, Stefan, et al.
Publicado: (2023)

Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis
por: Chen, Yan, et al.
Publicado: (2018)

Isolation of cancer‐associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma
por: Sha, Meng, et al.
Publicado: (2018)

Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma
por: Chen, Hua-Dong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_luskq772kj42id7rn3uaduj5or